Refika Kamuran Tekişoğulları has been working as a Biologist at the Turkish Health Institutes Presidency (TÜSEB) since 2019. She is currently pursuing a Ph.D. degree at the Biotechnology Institute of Ankara University. She received her M.Sc. degree in Biology from the Graduate School of Natural and Applied Sciences, Istanbul University, in 2010 and her B.Sc. degree in Biology from the Faculty of Science, Istanbul University, in 2006.
Her research interests include vaccine development, cell culture systems, viral isolation and infection models, neutralization assays, and quality control analyses. She has contributed to several national research projects, including the development and preclinical evaluation of a rabies vaccine candidate, the assessment of immune responses following MMR vaccination, the investigation of novel therapeutic targets for mesothelioma using single-cell RNA sequencing and CRISPR/Cas9 technologies, and laboratory studies conducted within the TURKOVAC Phase I and Phase II clinical trials.
She is a co-author of peer-reviewed publications on the safety, immunogenicity, and long-term booster responses of the inactivated SARS-CoV-2 vaccine TURKOVAC. Her current work focuses on viral vaccines, immunological assays, and cell culture technologies used in vaccine research and development.
Refika Kamuran Tekişoğulları has been working as a Biologist at the Turkish Health Institutes Presidency (TÜSEB) since 2019. She is currently pursuing a Ph.D. degree at the Biotechnology Institute of Ankara University. She received her M.Sc. degree in Biology from the Graduate School of Natural and Applied Sciences, Istanbul University, in 2010 and her B.Sc. degree in Biology from the Faculty of Science, Istanbul University, in 2006.
Her research interests include vaccine development, cell culture systems, viral isolation and infection models, neutralization assays, and quality control analyses. She has contributed to several national research projects, including the development and preclinical evaluation of a rabies vaccine candidate, the assessment of immune responses following MMR vaccination, the investigation of novel therapeutic targets for mesothelioma using single-cell RNA sequencing and CRISPR/Cas9 technologies, and laboratory studies conducted within the TURKOVAC Phase I and Phase II clinical trials.
She is a co-author of peer-reviewed publications on the safety, immunogenicity, and long-term booster responses of the inactivated SARS-CoV-2 vaccine TURKOVAC. Her current work focuses on viral vaccines, immunological assays, and cell culture technologies used in vaccine research and development.